Core Viewpoint - The arbitration decision by the Shenzhen International Arbitration Court has lifted the sales restrictions on AestheFill products for REGEN Biotech, Inc., a subsidiary of Aimeike, thereby facilitating the company's market expansion in China [1][2]. Group 1: Arbitration Decision - REGEN Biotech received a decision from the Shenzhen International Arbitration Court on January 29, which revoked a previous temporary measure that restricted its ability to sell AestheFill products in China [1]. - The decision confirms that REGEN's subsidiary, LIZHEN (Xiamen) Aesthetic Medical Technology Co., Ltd., retains the sales rights for AestheFill products in mainland China [2]. Group 2: Strategic Implications - The revocation of the temporary measures not only protects Aimeike's rights to sell AestheFill products in China but also accelerates the product's market deployment [2]. - Aimeike demonstrates a strategic capability of operating within legal frameworks while expanding its market presence, which is crucial for maintaining shareholder interests [2]. Group 3: Product and Market Development - Aimeike has established a robust sales network in the Chinese medical aesthetics market, which will enhance the product matrix and channel synergy with the introduction of AestheFill [3]. - The AestheFill and PowerFill products have accumulated years of international safety and efficacy data, providing a platform for Aimeike's international market expansion [3]. Group 4: Industry Trends - As the Chinese medical aesthetics market transitions to high-quality and standardized development, companies with comprehensive product matrices and strong R&D capabilities will continue to enjoy structural advantages [4]. - The recent legal victory for Aimeike underscores the importance of compliance in ensuring sustainable development within the increasingly regulated medical aesthetics industry [4].

Core Viewpoint - The performance of listed medical beauty companies in China shows significant divergence in the first half of 2025, with major players in the hyaluronic acid market facing growth bottlenecks, while companies in the recombinant collagen segment are experiencing substantial growth [1][2][7]. Group 1: Performance of Major Companies - Huaxi Biological reported revenue of 2.261 billion yuan, a year-on-year decline of 19.57%, and a net profit of 221 million yuan, down 35.38% [1][2]. - Haohai Biological achieved revenue of 1.304 billion yuan, a decrease of 7.12%, with a net profit of 211 million yuan, down 10.29% [1][2]. - Aimeike's revenue was 1.299 billion yuan, down 21.59%, with a net profit of 789 million yuan, a decline of 29.57% [1][2]. - In contrast, Jinbo Biological, the first stock of recombinant collagen on the Beijing Stock Exchange, reported revenue of 859 million yuan, an increase of 42.43%, and a net profit of 392 million yuan, up 26.65% [1][2]. - Giant Biological's revenue reached 3.113 billion yuan, a year-on-year increase of 21.66%, with a net profit of 1.182 billion yuan, up 20.23% [1][2]. Group 2: Market Trends and Competition - The medical beauty market in China has seen rapid growth, with the market size increasing from 99.3 billion yuan in 2017 to 189.2 billion yuan in 2021, reflecting a compound annual growth rate of 17.5% [4]. - The competition in the hyaluronic acid sector has intensified, leading to price reductions and impacting the performance of leading companies [4][6]. - The demand for aesthetic products is evolving, with a shift towards user-oriented solutions and a growing emphasis on product innovation and technology [3][7]. Group 3: Strategic Adjustments and Innovations - Huaxi Biological is shifting its marketing strategy to focus on brand building and consumer engagement through platforms like Xiaohongshu and WeChat, moving away from price-driven promotions [5]. - Haohai Biological is also adapting its product offerings, with new high-end hyaluronic acid products showing promising market performance [6]. - The recombinant collagen market is projected to grow significantly, with estimates suggesting it will reach 585.7 billion yuan by 2025, driven by new product launches and market expansion [8][9]. Group 4: Regulatory and International Expansion - The medical beauty industry is witnessing an increase in compliant products, with several companies obtaining third-class medical device registration certificates, enhancing market offerings [10][11]. - Companies like Huaxi Biological and Haohai Biological are actively pursuing international markets, with Huaxi reporting significant revenue from overseas operations [11][12]. - Aimeike's acquisition of a majority stake in a South Korean company highlights the trend of domestic firms expanding their global footprint [12].